



February 25, 2026

M/s. National Stock Exchange of India Ltd
Mumbai- 400 051

Scrip Code: **NATCOPHARM**

Dear Sir,

Sub: Clarification /Confirmation on news item appearing in “Media / Publication”

Ref : Your letter No. NSE/CM/Surveillance/16498 dated February 24, 2026

With reference to above cited subject, we bring to your notice the following clarification:

- a) *Whether such negotiations/events were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order from the start of negotiations/events till date.*

The company has disclosed about the receipt of approval from the Central Drugs Standard Control Organisation (CDSCO) for Semaglutide in India on February 14, 2026, in this regard we bring to your notice that we are working with different marketing partners to launch the product in the month of March 2026 in India and the partnership for the said product with Eris Lifesciences Ltd is in the ordinary course of business which has no material impact on the operations of the company.

- b) *Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the movement in the trading, if any? Further, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under regulation 30 of the SEBI (LODR) Regulations, 2015.*

No

- c) *The material impact of this article on the Company*

As of now, no material financial impact of the article on the company.

The company has been consistently making disclosures to the Stock Exchanges as required under Regulation 30 of the SEBI (LODR) Regulations, 2015 and continues to adhere to the said regulations.

This is for your information.

Yours faithfully

For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer